Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Brain Imaging01:14

Brain Imaging

797
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
797

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The neurobiology of survivorship: Cognitive consequences of modern oncology.

Neuro-oncology advances·2026
Same author

Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas.

Journal of neuro-oncology·2026
Same author

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Pituitary Stalk Lesion Sampling by Transsphenoidal Posterior Lobe Biopsy: A Case Series.

Journal of neurological surgery. Part B, Skull base·2026
Same author

From barrier to bridge: a scoping review on the methods, clinical efficacy, and safety of blood-brain barrier disruption in treating high-grade glioma.

Journal of neuro-oncology·2026
Same author

Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: Feb 27, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K

Tumor Treating Fields in Neuro-Oncological Practice.

Maciej M Mrugala1,2,3,4, Jacob Ruzevick5, Piotr Zlomanczuk6

  • 1Departments of Neurological Surgery, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA. mrugala.maciej@mayo.edu.

Current Oncology Reports
|July 1, 2017
PubMed
Summary

Electric fields, specifically tumor treating fields (TTF), inhibit cancer cell growth and are effective in treating glioblastoma (GBM) with minimal toxicity. This review covers TTF evidence in neuro-oncology.

Keywords:
BevacizumabGlioblastomaNovoTTFTumor treating fields

More Related Videos

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Experiment Videos

Last Updated: Feb 27, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Area of Science:

  • Biophysics
  • Oncology
  • Medical Technology

Background:

  • Electric fields exhibit diverse biological effects, including tissue damage and anti-mitotic activity.
  • Specific frequencies (100-300 KHz) disrupt mitosis and induce cell death.
  • Cancer cell growth, in vitro and in vivo, is inhibited by electric field application.

Purpose of the Study:

  • To review the evidence supporting the use of tumor treating fields (TTF) in neuro-oncologic practice.
  • To highlight the efficacy and safety of TTF for brain tumor treatment.

Main Methods:

  • Review of clinical trials and scientific literature on TTF for glioblastoma (GBM).
  • Analysis of data on TTF's anti-mitotic effects and impact on cancer cell lines.
  • Evaluation of clinical outcomes and toxicity profiles from TTF treatment in GBM patients.

Main Results:

  • TTF demonstrates anti-mitotic activity and inhibits cancer cell proliferation.
  • Clinical trials in recurrent and newly diagnosed GBM show TTF is an active treatment modality.
  • TTF is associated with minimal toxicity in patients with brain tumors.

Conclusions:

  • Tumor treating fields (TTF) represent a viable and effective treatment option for glioblastoma (GBM).
  • The evidence supports the integration of TTF into neuro-oncologic practice.
  • TTF offers a novel therapeutic approach with a favorable safety profile for brain tumor patients.